We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
MGUO | Magnum Mining and Exploration Ltd | 0.008 | 0.005 | 166.67% | 4,677,508 | 12 |
FRSOA | Forrestania Resources Ltd | 0.002 | 0.001 | 100.00% | 400,000 | 1 |
LPDOE | Lepidico Ltd | 0.002 | 0.001 | 100.00% | 500,000 | 1 |
BUR | Burley Minerals Ltd | 0.155 | 0.069 | 80.23% | 2,004,296 | 151 |
ERW | Errawarra Resources Ltd | 0.099 | 0.039 | 65.00% | 17,347,151 | 807 |
M4MOB | Macro Metals Ltd | 0.03 | 0.01 | 50.00% | 6,070,454 | 29 |
WHKO | WhiteHawk Limited | 0.003 | 0.001 | 50.00% | 1,927,961 | 10 |
LV1OA | Live Verdure Ltd | 0.30 | 0.10 | 50.00% | 243,607 | 10 |
SRNOD | Surefire Resources NL | 0.003 | 0.001 | 50.00% | 2,000,000 | 2 |
APC | Australian Potash Limited | 0.0015 | 0.0005 | 50.00% | 6,183,514 | 14 |
IND | Industrial Minerals Limited | 0.26 | 0.085 | 48.57% | 653,943 | 55 |
Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors ...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). The approval is based on the pivotal TRIDENT-1 study, an open-label, single-arm, Phase 1/2 trial that evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that HeartBeam AIMIGo™ has been selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. The awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 62,769.70 | 1,321.70 | 2.15% | 1.23T | 3,265,851,646 |
ETH | Ethereum | 2,965.28 | 37.78 | 1.29% | 356.38B | 1,646,735,517 |
USDT | Tether USD | 0.99964 | 0.00015 | 0.02% | 97.8B | 105,992,675 |
BNB | Binance Coin | 593.44 | -0.275236 | -0.05% | 93.92B | 304,321,988 |
SOL | Solana | 146.07 | 1.77 | 1.23% | 64.43B | 854,457,633 |
STETH | stETH | 2,964.42 | 38.67 | 1.32% | 29.1B | 3,418,021 |
USDC | USD Coin | 0.99997 | -0.00001 | 0.00% | 28.07B | 453,335,683 |
XRP | Ripple | 0.5076 | 0.00816 | 1.63% | 27.63B | 253,247,556 |
TONCOIN | Wrapped TON Coin | 7.29 | 0.324763 | 4.66% | 25.51B | 431,784,884 |
DOGE | Dogecoin | 0.1441 | 0.0016 | 1.12% | 20.57B | 331,940,100 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions